A pilot study of AT101 (humanized anti-CD19 chimeric antigen receptor T cell) in anti-CD19 CAR T therapy-exposed patients with relapsed or refractory diffuse large B cell lymphoma
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.